title: Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor.
abstract: Tyrosine kinase inhibitors (TKIs) are associated with various adverse cutaneous reactions, including pigmentary changes. Radotinib is a novel and selective BCR-ABL1 TKI, which has shown activity and safety in the treatment of patients with chronic myeloid leukaemia resistant or intolerant to imatinib. A 69-year-old Korean man presented with lentiginosis after taking radotinib for 6 months. On histopathological examination, the numbers of melanocytes and melanin pigment were found to be increased due to c-KIT activation, consequently upregulating microphthalmia-associated transcription factor. This finding is in contrast to previous reports analysing the mechanisms of previously reported tyrosine kinase inhibitors inhibiting c-KIT.
authors.affiliation: Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: K H
authors.identifier: http://orcid.org/0000-0002-7692-4520
authors.initials: KH
authors.lastname: Won
authors.affiliation: Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: S Y
authors.initials: SY
authors.lastname: Jo
authors.affiliation: Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: S E
authors.initials: SE
authors.lastname: Chang
mesh_terms: D000368:Aged; D001132:Arm; D001549:Benzamides / Q000009:adverse effects*; D005148:Facial Dermatoses / Q000139:chemically induced*; D006801:Humans; D007911:Lentigo / Q000139:chemically induced*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011719:Pyrazines / Q000009:adverse effects*
chemical_list: C000606751:4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide; D001549:Benzamides; D047428:Protein Kinase Inhibitors; D011719:Pyrazines